Annexin V is a Ca 2+ -dependent phospholipid binding protein. Although it has been shown to inhibit protein kinase C (PKC) in cell-free systems, its role in the intact cell is unclear. A stable MCF-7 human breast cancer cell overexpression system was established to investigate the function of annexin V. In these cells, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced phosphorylation and kinase activity of ERK1/2 were suppressed. Morphological changes induced by TPA were reduced by annexin V overexpression as well as by the pan-PKC inhibitor, bisindolylmaleimide I, and by the mitogenactivated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor, PD98059. TPA-induced MEK1/2 and Raf-1 phosphorylation were reduced in these cells. The TPA-enhanced active Ras, and its association with Raf-1, were reduced. TPA treatment of MCF-7 cells caused an increased association of Shc with Grb2. However, this increased association was prevented in the annexin V-overexpressors. p21 WAF/CIP1 is responsible for inhibition of cell cycle progression in MCF-7 cells. TPA induced the expression of p21 WAF/CIP1 to a greater extent in MCF-7 parent and control plasmid cells than in annexin V overexpressors. PD98059 inhibited this increase, suggesting that TPA upregulation of p21 WAF/CIP1 occurs via the MEK pathway, and that annexin V overexpression blunts it. This work shows that annexin V overexpression suppresses the TPA-induced Ras/ERK signaling by inhibiting at/or upstream of Shc, possibly through the inhibition of PKCs. Oncogene (2000) 19, 2904 ± 2912.
Introduction
Activation of the GTP binding protein Ras with various extracellular stimuli results in a cascade of phosphorylation reactions involving Raf, mitogenactivated protein kinase/ extracellular signal-regulated kinase kinases (MEK1/2) and mitogen-activated protein kinases (MAPKs; extracellular signal-regulated kinases, ERK1/2) (Cobb and Goldsmith, 1995; Marshall, 1994 ), which is a major step in mitogenic signaling (Pages et al., 1993; Meloche et al., 1992) . Recent studies showed that this Ras/ERK signaling pathway was also activated by 12-O-tetradecanoylphorbol-13-acetate (TPA) (Nori et al., 1992; Troppmair et al., 1994) , involving serine phosphorylation of Shc (El-Shemerly et al., 1997) . One of the adaptor proteins, Shc, relays receptor tyrosine kinase (RTK)-induced signals through the Ras/ERK transduction pathway (van der Geer and Pawson, 1995) . Following association with the active RTK, Shc is phosphorylated in speci®c tyrosine residues and it forms a complex with another adaptor protein Grb2 (Rozakis-Adcock et al., 1992) . This complex recruits the Ras guanine nucleotide exchange factor (SOS) to the plasma membrane (Buday and Downward, 1993) , which activates Ras by catalyzing the Ras-GTP for Ras-GDP exchange.
Numerous studies have shown that TPA activates protein kinase C (PKC), one of the key enzymes in signal transduction, cell dierentiation and proliferation, mimicking the physiological lipid metabolite diacylglycerol (Dekker and Parker, 1994) . This is the only known function of TPA in the cell, although the entry site of the TPA signal in the pathway is still unclear. In MCF-7 breast cancer cells, TPA also induces growth arrest accompanied by dierentiation (Valette et al., 1987; Abe and Kufe, 1986; Alblas et al., 1998) , and inhibition of the Ras/ERK pathway can alleviate the inhibitory activity of TPA on S phase entry (Troppmair et al., 1994) . This inhibitory property in MCF-7 cells is attributed to the strong stimulatory eect of TPA on p21 WAF/CIP1 production (Dufourny et al., 1997) . This probably results in inactivation of the cyclin D1-cdk4 complex.
The annexins, Ca
2+
-dependent phospholipid binding proteins, comprise at least 13 structurally related members that share a common core domain, including four or eight internal repeats of a conserved 70-aminoacid sequence, which are supposed to be Ca 2+ and phospholipid binding sites (Raynal and Pollard, 1994) , and a variable N-terminal domain. Although annexin V is widely expressed and has been attributed many functions, including an involvement in cell proliferation (Karube et al., 1995) and signal transduction (Utsumi, 1992; Shibata et al., 1992a Shibata et al., ,b, 1997 , its precise biological role in the living cell has not been de®ned. Interestingly, annexin V inhibits PKC activity in vitro (Rothhut et al., 1995; Raynal et al., 1993; Schlaepfer et al., 1992; Shibata et al., 1992a,b) .
PKCs represent one of Ser/Thr protein kinase families. The PKC family is composed of more than 11 members that can be classi®ed into three groups:
conventional, novel and atypical groups. Conventional (a, bI, bII and g) and novel (d, e, y and Z) PKCs can be activated by TPA and only conventional PKCs have a requirement for Ca 2+ for overall functions. It is interesting that annexins also require Ca 2+ to bind the phospholipid interface. Since both annexin V and PKCs are found in the cytosol and translocate to the membrane interface on increases in intracellular Ca 2+ levels (Raynal et al., 1996) , annexin V might be one of the modulators of PKC activity (Dubois et al., 1996 (Dubois et al., , 1998 . In the present study, we have investigated the function of annexin V in the cell. We have taken the approach to establish annexin V-stably overexpressing MCF-7 human breast cancer cells. TPA-induced Ras/ ERK signaling is suppressed in these cells and this inhibition occurs at the level or upstream of Shc.
Results

Overexpression of annexin V in MCF-7 cells
Overexpression of annexin V was con®rmed with EIA and immunoblot analysis. The full coding fragment of human annexin V cDNA was introduced into pcDNA3.1(7) to generate the expression plasmid pcDNA3.1(7)AxV. After cloning twice, four stable cell lines were obtained (clones #90-6, #90-9, #90-11 and #102-5) in which the expression levels of annexin V were from 7.65 ± 10.48 times higher than that in parent cells. On the other hand, control plasmid clones (clones #69 and 80) expressed almost the same levels of annexin V as parent cells. Annexin V migrated as a 36 kDa single band on immunoblotting of the dierent clones (Figure 1 ).
TPA-induced MAPK phosphorylation and MAPK activity are inhibited in annexin V overexpressing cells
Phosphorylation of both ERK-1 and ERK-2 kinases in response to 10 and 50 nM TPA occured to the same or to a slightly greater extent in control plasmid clones (clones #69 and #80) than in parent MCF-7 cells (Figure 2a ). In sharp contrast annexin V overexpressors (clones #90-9 and #102-5) showed a much lower extent of phosphorylation ( Figure 2a ). ERK-1 and ERK-2 activities were determined as a whole MAPK activity with an immune complex kinase assay, which was evaluated as a phosphorylation level of myelin basic protein (MBP). Annexin V overexpressing cells also showed a reduced MAPK activity (Figure 2b ,c).
TPA-induced morphological changes are blunted in annexin V overexpressing cells TPA induces various types of morphological changes depending on cell type and duration of stimuli (Kato et al., 1988) . MCF-7 cells have been found to be highly sensitive to growth inhibition by phorbor esters. They occupy wider space for attachment several hours after 5 ± 10 nM TPA stimulation, and become star-shaped with dendritic projections on 2 ± 3 days, followed by apoptosis. Annexin V overexpressing clones failed to show these morphological changes (Figure 3 ), which were also prevented by 50 mM of MEK1 inhibitor PD98059 (New England Biolabs, Inc., data not shown) in parent MCF-7 cells. Total intracellular protein was extracted from parent MCF-7 cells, annexin V-stably expressing clones (#90, #102, #90-6, #90-9, #90-11, #102-5) and control clones (#69, #80). They were analysed by immunoblot and EIA as described in Materials and methods to determine annexin V expression levels. Data by EIA are presented as the fold change of normalized values of annexin V with total protein relative to parent (AvV Ratio). These data are expressed as means of triplicate. Immunoblot analysis of annexin V was performed with equal amounts (4.5 mg/lane) of total protein from the same samples. They were submitted to 10% SDS ± PAGE followed by immunoblotting using monoclonal antiannexin V antibody (A46) diluted at 1 : 1000 in TBST with 5% BSA /well, serum starved and treated with 10 nM TPA for 60 min or 50 nM TPA for 15 min as described in Materials and methods. After treatment, equal amounts (10.7 mg/lane) of total protein were loaded onto 10% SDS ± PAGE and immunoblot analysis was performed to detect the phosphorylation of ERK1 and ERK2 using anti-phosphorylated ERK1/2 antibody at 1 : 1000 dilution. (clone #90-9) . The level of whole ERK1/2 and MEK1/ 2 antigens recognized by the appropriate antibodies were decreased in parent and control cells, although their quiescent levels in these three cell lines were almost the same. The lower levels of phosphorylated ERK1/2 in annexin V overexpressors was accompanied by lower levels of phosphorylated Raf identi®ed as mobility shift on SDS ± PAGE ( Figure 5 ).
TPA-induced Ras activation fails to occur in annexin V overexpressing cells
Activated Ras was quanti®ed as anity precipitated Ras with immobilized Raf on agarose. Bound Ras was assayed by immunoblotting with anti-Ras antibody, which is proportional to the amount of active form Ras. Annexin V overexpression blunted the activation of Ras in response to TPA stimulation, which was observed in parent and control cells (Figure 6a) , although the expression level of Ras itself was higher in annexin V transfectants (Figure 6b ). Figure 4 Time course of TPA-induced MAPK and MEK phosphorylation. Cells were plated on 6-well cluster plates at 2610 5 / well, serum starved and cell extracts were prepared as described in Materials and methods at the indicated time point of 5 nM TPA treatment. Equal amounts (9.7 mg/lane) of total protein were applied to 10% SDS ± PAGE and immunoblotting using antiphosphorylated ERK1/2 antibody, anti-ERK1/2 antibody, anti-phosphorylated MEK1/2 antibody and anti-MEK1/2 antibody at 1 : 1000 dilution (a). Densitometric analysis of phosphorylated ERK1/2 (b) and phosphorylated MEK1/2 (c) bands in Figure 5a was shown. Graphed data are presented as the proportion of the density of each band relative to that of parent cells at 120 min /well and cell extracts were prepared as described in Materials and methods after 30 or 60 min of 5 nM TPA treatment. Equal amounts (10.4 mg/lane) of total protein were resolved on 6% SDS ± PAGE followed by immunoblotting using anti-Raf-1 antibody at 1 : 1000 dilution Annexin V overexpression suppresses the Shc-Grb2 association in MCF-7 cells
To elucidate how annexin V suppresses Ras/ERK signaling, we analysed the eect of TPA stimulation on two Ras-regulatory adapter proteins, Shc and Grb2, in control and annexin V stably transfected MCF-7 cells. As described in Materials and methods, anti-Shc immunoprecipitates were analysed by immunoblotting with anti-Grb2 antibody and anti-phosphotyrosine antibody. As shown in Figure 7 , Shc-Grb2 association was decreased to some extent in the annexin V overexpressing cells, although phosphorylation levels of Shc in tyrosine residues showed no remarkable changes and Grb2 was expressed to a higher extent in annexin V stably expressing cells than in control and parent cells.
Effect of annexin V overexpression on p21
WAF1/CIP1 and Ras-GTPase-activating protein (GAP) induction by TPA TPA inhibits cell cycle progression in MCF-7 cells. We investigated the eect of annexin V overexpression on the induction of cyclin D1 (data not shown) and p21 WAF/CIP1 by TPA as parameters for cell cycle progression, because TPA has been reported to induce synthesis of these proteins (Devente et al., 1995; Dufourny et al., 1997) . Induction levels of these two proteins in annexin V overexpressing cells were less than those in control and parent cells, and their basal levels were relatively high (Figure 8a, b) . Preincubation with the speci®c MEK1 inhibitor PD98059 rescued the induction of both proteins to some extent. On the other hand, the expression levels of Ras-GAP, which is thought to be a down-regulator of Ras by stimulating its intrinsic GTPase activity, were not aected by TPA in all cell lines (Figure 8a ).
Effect of PKC inhibitors on TPA-induced morphological changes and MAPK phosphorylation in MCF-7 cells
The eect of two dierent kinds of PKC inhibitors, bisindolylmaleimide I (GF-109203X) and GoÈ 6976, on TPA-induced morphological changes in MCF-7 cells was investigated. Only pan-PKC inhibitor, bisindolylmaleimide I, inhibited the morphological changes, while conventional PKC speci®c inhibitor, GoÈ 6976 did not (Figure 9a) . A similar inhibition was observed in the case of TPA-induced ERK1/2 phosphorylation Cells left untreated or treated with 5 nM TPA for 1 h were lysed and cell extracts were immunoprecipitated with a polyclonal antiShc antibody. Immunoprecipitates were analysed by immunoblotting using anti-Grb2 antibody as described in Materials and methods (top). The same blot was reprobed with monoclonal anti-Shc antibody at 1 : 250 dilution (upper middle) and with recombinant anti-phosphotyrosine antibody at 1 : 1000 dilution (lower middle). Total cell extracts with the same treatment of TPA were prepared and analysed by immunoblotting with antiGrb2 antibody at 1 : 1000 dilution as described in Materials and methods (bottom) and Ras-GAP induction by TPA. Cells were seeded on 6-well cluster plates at 2.0610 5 /well and cultured for 2 days. After serum starvation, cells were cultured for 7 h in the presence of 10 nM TPA with or without preincubation with 40 mM PD98059 (PD) for 1 h. Cell extracts were prepared as described in Materials and methods and equal amounts (27.8 mg/lane) of total protein were applied to 4 ± 20% SDS ± PAGE and immunoblotting using anti-p21 WAF/CIP1 antibody and anti-Ras-GAP antibody at 1 : 100 and 1 : 200 dilution respectively (a). Densitometric analysis of p21 WAF/CIP1 bands in Figure 9a was shown. Graphed data are presented as the proportion of the density of each band relative to that of parent cells without TPA (b) (Figure 9b ). Bisindolylmaleimide I and PKC d speci®c inhibitor rottlerin as well as the MEK inhibitors PD98059 and U0126 all inhibited phosphorylation of ERK1/2 in a dose-dependent manner (compare`b' tò c'). Culture medium with inhibitors contains the same amount of DMSO as a solvent (0.02 or 0.04%). These concentrations of DMSO had no in¯uence on the induction of ERK1/2 phosphorylation.
Discussion
Annexin V is a member of a large family of proteins that interact with acidic phospholipids in a Ca 2+ -dependent manner. An interaction between annexin V and PKC has been suggested by studies in cell-free systems demonstrating the ability of annexin V to inhibit the PKC-catalyzed phosphorylation of many substrates in cell-free systems in the presence or absence of TPA (Rothhut et al., 1995; Raynal et al., 1993; Schlaepfer et al., 1992; Shibata et al., 1992a) . Since relatively few endogenous physiological inhibitors of PKC activity have been reported, the study of the mode of action of annexin V may have some interest in understanding the physiology of these inhibitory activities. A substrate depletion mechanism is widely accepted as the explanation for most inhibitory studies (Buckland and Wilton, 1998) .
The mechanism of action of annexin V within the cell is not so far clearly understood, but suggestions have been made for its possible actions on phospholipid sequestration (Dubois et al., 1998) or competition for phospholipids that normally bind PKC (Raynal et al., 1993) . Unlike other annexins, annexin V has never been demonstrated to be a substrate for PKCs (Comera et al., 1989; Kaplan et al., 1988) . This suggests that this protein may rather act as an inhibitor of these kinases (Shibata et al., 1992b) . While annexin VI has been demonstrated to be connected with cell proliferation (Theobald et al., 1994 (Theobald et al., , 1995 , annexin V has been implicated in many functions, including signal transduction (Rothhut et al., 1995; Shibata et al., 1992a Shibata et al., ,b, 1997 , but only in cell-free systems. Therefore we set out to generate stable clones expressing annexin V to study the eect of the PKC activator on these clones compared to control plasmid transfected and wild-type MCF-7 cells.
One of the tyrosine kinase-activated signal transduction pathway, the Ras/ERK pathway, includes the plasma membrane-bound small guanine nucleotide /well and cultured for 2 days. After serum starvation, cells were cultured for 30 min (a) or 60 min (b,c) in FBS-free DMEM alone or in that with 10 nM TPA. 1 mM bisindolylmaleimide I, 1 mM GoÈ 6976, 10 mM rottlerin (Calbiochem, San Diego, CA, USA), 20 mM PD98059 or 2 mM U0126 (Calbiochem, San Diego, CA, USA) were added 1 h before TPA treatment, and the concentration of DMSO, which was used as a solvent for inhibitors, was adjusted to 0.02% when indicated DMSO+ (a,b). The concentrations of inhibitors and DMSO in`c' were twice as much as those in`b'. Cell extracts were prepared as described in Materials and methods and equal amounts (35.8 mg/lane) of total protein were applied to 4 ± 20% SDS ± PAGE and immunoblotting using anti-phosphorylated ERK1/2 antibody at 1 : 1000 dilution binding protein Ras, the protein kinases Raf, the MAP-kinase kinase (MEK) and MAP kinases (ERK1/ 2) (Dickson and Hafen, 1994; Marshall, 1994) . This signaling pathway is essential for cell metabolism, growth, and dierentiation (Alblas et al., 1998; Pages et al., 1993; Meloche et al., 1992) and numerous oncogenes share the activation of MAPK as a common pathway (Waskiewicz and Cooper, 1995) . However, to our knowledge, no reports have been published on the relationship between annexins and Ras/ERK signaling. Our results show that overexpression of annexin V protein in MCF-7 cells inhibited both TPA-induced phosphorylation and kinase activity of ERK1/2. Furthermore TPA-induced MEK1/2 phosphorylation was also suppressed in these cells.
Two proteins, Raf and Shc, are likely substrates for PKC in receptor tyrosine kinase-Ras/ERK signaling pathway (Kolch et al., 1993; El-Shemerly et al., 1997) . In NIH3T3 ®broblasts PKC phosphorylates Raf-1 and stimulates its kinase activity (Kolch et al., 1993) , although Raf-1 phosphorylation by PKC in vitro does not lead to MEK activation (Macdonald et al., 1993) . In our study, TPA-induced Raf-1 phosphorylation was not signi®cant in annexin V overexpressing cells. However, it is not clear whether annexin V directly inhibits the phosphorylation and activation of Raf induced by PKC, since Ras/ERK signaling was inhibited upstream of Raf in this system. Ras functions as a regulated membranebound anchor for Raf, and other signals also contribute to Raf activation (Leevers et al., 1994) , although details are still unclear. Membrane-localized Raf is activated by a Ras-independent mechanism (Leevers et al., 1994) , since Ras-GTP itself does not stimulate the kinase activity of Raf in vitro (Zhang et al., 1993) and once Raf is activated, it does not require Ras to exhibit its activity (Leevers et al., 1994) . It has been suggested that a lipid activator may bind to the N-terminal regulatory domain of Raf (Bruder et al., 1992) . If the binding of Ras to acidic phospholipid serves as an anchor for Raf or the interaction of Raf with another molecule such as a lipid (Kolch et al., 1993; Sozeri et al., 1992; Fabian et al., 1993; Bruder et al., 1992) , especially a phospholipid, is needed for its activation, annexin V might inhibit Raf activation by means of its depletion mechanism.
GTP-bound Ras interacts with the amino-terminal regulatory domain of Raf (Zhang et al., 1993; Warne et al., 1993; Vojtek et al., 1993; Van Aelst et al., 1993) as demonstrated by their coimmunoprecipitation from ligand-stimulated cells (Hallberg et al., 1994; Finney et al., 1993) . Using this property, the active form of Ras was quanti®ed as anity precipitate with Rafconjugated agarose. Upon TPA stimulation, the level of this active form Ras in annexin V overexpressing cells was less than that in parent as well as control cells, consistent with an inhibition of the Ras/ERK pathway by annexin V at or upstream of Ras. We also found that the amount of Shc associated with Grb2 is controlled by expression levels of annexin V and that the inhibition of Ras/ERK signaling processes by annexin V can be attributed to the decreased association between Shc and Grb2. Because the ShcGrb2 association is an early signaling event preceding Ras activation, annexin V might down-regulate Ras activation through its eects on the Shc-Grb2 association. These data are consistent with the fact that TPA signal is fed at or upstream of Shc to activate the RAS/ ERK signaling pathway which involves serine phosphorylation of Shc (El-Shemerly et al., 1997) .
Phorbol esters serve as hydrophobic anchors to recruit PKCs to the membrane; they cause a dramatic increase in anity of the enzyme to the membrane, which is accompanied by activation of conventional and novel PKCs (Newton, 1995) . However atypical PKCs have been reported not to respond to phorbol esters in vivo and in vitro (Nishizuka, 1995) . Therefore conventional and/or novel PKCs are supposed to be involved in the activation of Ras/ERK pathway induced by TPA. Although it is less likely that atypical PKCs are involved in the annexin V inhibition, conventional as well as novel and atypical PKCs must be considered, since annexin V itself inhibits PKCs by a substrate depletion mechanism by binding to acidic phospholipids (Buckland and Wilton, 1998) , which also enhance the activation of conventional, novel and atypical PKCs (Newton, 1995) .
MCF-7 cells are known to express the following PKCs: a, d, E, Z and z. To investigate which PKC group is responsible for TPA-induced morphological changes, MCF-7 cells were pretreated with two dierent kinds of PKC inhibitors, bisindolylmaleimide I and GoÈ 6976 before TPA treatment. Only bisindolylmaleimide I, which is an inhibitor of PKC a, b I , b II , g, d, E and z at as low as 1 mM, blunted the TPAinduced morphological changes, whereas GoÈ 6976, speci®c for PKCa, b I , failed to prevent and/or reverse the TPA-induced morphological changes. Considering that TPA cannot activate atypical PKCs, like PKC z, these changes are tentatively attributed to the activation of novel PKCs (d and/or E). Since the MEK1 inhibitor PD98059, which is one of the Ras/ERK pathway inhibitors, as well as overexpression of annexin V both prevented the TPA-induced morphological changes, annexin V may inhibit the Ras/ERK signaling through the inhibition of family of`novel PKCs'. That is to say, activation of novel PKCs may be necessary to lead to the activation of the Ras/ERK pathway in MCF-7 cells. This is also supported by the ®ndings that TPA-induced ERK1/2 phosphorylation was impaired by bisindolylmaleimide I and also by the PKC d speci®c inhibitor, rottlerin, as well as by the MEK inhibitors PD98059 and U0126, but not by GoÈ 6976. This strongly suggests that PKC d is a most likely candidate of TPA targeted PKC isoforms in this system. We suggest that since Ras/ERK signaling pathway plays an important role in cell growth and dierentiation, and TPA induces growth arrest and dierentiation (Valette et al., 1987; Abe and Kufe 1986 ) through the Ras/ERK pathway (Alblas et al., 1998) ,`novel PKCs' may inhibit cell proliferation and induce dierentiation via the Ras/ERK pathway.
TPA is a mitogen of some cell lines in vitro (Herschman et al., 1989; Menapace et al., 1987; Winkelstein et al., 1986) , but it has growth inhibitory activity in other cell types, including the MCF-7 cells, in which it also activates MAPK (Younus and Gilchrest, 1992; Arita et al., 1994; Valette et al., 1987) . The anti-proliferative property of TPA in MCF-7 cells is accounted for by the MAPK-dependent stimulation of the synthesis of p21
, an inhibitor of cyclin/cyclin-dependent kinase complexes (Dufourny et al., 1997) . Our data also showed the upregulation of p21
induced by TPA in MCF-7 cells. The Oncogene Annexin V inhibits MAPK pathway H Sato et al suppression of this upregulation in annexin V overexpressing cells demonstrated here is probably to be attributed to the inhibition of the Ras/ERK pathway by annexin V. In fact, annexin V inhibited the TPAinduced MAPK activation, and p21 WAF/CIP1 induction is thought to be MAPK-dependent. In our system, the TPA-induced p21 WAF/CIP1 production was blunted by the MEK inhibitor PD98059.
Finally, our studies may be relevant to the physiological function of annexin V, even though the stable clones were generated to overexpress this protein. This is because the concentration of annexin V in many cell types exceeds the concentrations required to achieve PKC inhibition in vitro (Schlaepfer and Haigler, 1990) .
Taken together, our results suggest that annexin V can prevent TPA induced Ras/ERK signaling by inhibiting at, or upstream of Shc, possibly through an action involving PKCs. The mechanism responsible for this action of annexin V remains to be discovered.
Materials and methods
Antibodies
Monoclonal anti-annexin V antibody (A46) was a gift from Kowa Research Institute (Tsukuba, Japan). Polyclonal antiphosphorylated ERK1/2, anti-ERK1/2, anti-phosphorylated MEK1/2 and anti-MEK1/2 antibodies were purchased from New England Biolabs, Inc. (Beverly, MA, USA). Monoclonal anti-phosphorylated MBP antibody was from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal antiRaf-1, anti-Ras, anti-Grb2, anti-Shc, anti-Ras-GAP, polyclonal anti-Shc and recombinant anti-phosphotyrosine (RC 20: HRPO) antibodies were from Transduction Laboratories (Lexington, KY, USA). Monoclonal anti-cyclin D1 and antip21 WAF/CIP1 antibodies were from PharMingen (San Diego, CA, USA). Horseradish peroxidase-coupled antibodies (goat anti-mouse and anti-rabbit) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Cell line and culture conditions
Human breast cancer cell line MCF-7 was obtained from American Type Culture Collection (Rockville, MD, USA) and routinely cultured as adherent monolayers in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a 378C, 5% CO 2 humidi®ed incubator.
Determination of intracellular protein and annexin V concentrations
Cells plated in 6-well cluster plates were washed twice with PBS, scraped, and sonicated on ice for 15 s in 0.5 ml of PBS (pH 7.4) containing 25 mM EDTA and 0.05% Tween 20. The extract was centrifuged at 15 800 g for 10 min and the amount of annexin V in the supernatant was quanti®ed by sandwich EIA as described before (Shibata et al., 1997) . Protein concentration was determined according to Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA), using BSA as a standard. The same sample was applied for immunoblotting to con®rm the expression level of annexin V.
Construction of mammalian expression plasmid encoding human annexin V
Recombinant pUC118 plasmid, pMKT7, containing full coding region of human annexin V cDNA was generously provided by Kowa Research Institute (Tsukuba, Japan). In NcoI ± HindIII (Boehringer Mannheim, Indianapolis, IN, USA) fragment of pMKT7, blunt end was introduced at 5' NcoI site. This full coding fragment was cloned into the pcDNA3.1(7) mammalian expression vector (Invitrogen, Carlsbad, CA, USA) to generate pcDNA3.1(7)AxV by digestion with EcoRV and HindIII restriction endonucleases and ligation with T4 DNA ligase (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Plasmid for transfection was prepared with Plasmid Midi or Maxi Kits (QIAGEN Inc., Valencia, CA, USA).
Construction of stable cell lines
MCF-7 cells were plated in 6-well cluster plates at 2610 5 /well in 2 ml of DMEM supplemented with 10% FBS. Twentyfour hours after seeding, 1 mg of pcDNA3.1(7)AxV expression plasmid or alternatively 1 mg of empty plasmid was transfected into the cells using LIPOFECTAMINE PLUS transfection reagent (Life Technologies, Rockville, MD, USA) according to the manual's instructions. After 3 h incubation, DMEM with 20% FBS was added to bring the ®nal concentration of FBS to 10%. Twenty-four hours after the beginning of transfection, the transfected cells were passaged into 100 mm culture dishes with fresh culture medium, and on day 2, 1 mg/ml of G418 was added to select for expression of the transfected anti-G418 resistance gene. After 6 weeks, 10 clones were isolated and expanded as annexin V stably expressing clones out of 111 G418-resistant clones, and 2 clones as control (#69, #80). Two of these 10 positive clones (#90, #102) were subcloned, and after 2 weeks, four clones were isolated. Annexin V expression levels were monitored with EIA.
Serum starvation and preparation of total cell extracts for immunoblotting
Cells were seeded and cultured on 6-well cluster plates in 2 ml of DMEM with 10% FBS for 3 days. After overnight serum starvation, medium was replaced by serum-free medium 2 h before experiments. Stock solution of TPA in DMSO was at 10 72 M. Further dilution of the 10 72 M TPA was obtained by adding serum-free DMEM to yield a 10 76 M TPA solution. Cell treatment was performed by adding appropriate aliquot of this 10 76 M TPA solution directly to culture medium to obtain the desired concentration of TPA, as speci®ed. Solvent DMSO had no in¯uence on the phosphorylation as well as the activity of ERK1/2. After washing with cold PBS once, treated cells were lysed by adding 100 ml of 16 SDS sample buer (62.5 mM Tris-HCl, 2% SDS, 10% glycerol, 2.5% 2-mercaptoethanol, 0.1% bromophenol blue, pH 6.8), scraped and sonicated for 5 s on ice. These samples were boiled for 5 min and kept on ice before electrophoresis and immunoblotting.
SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblot analysis
Samples were prepared in 16 SDS sample buer and boiled for 5 min prior to electrophoresis. SDS ± PAGE was performed using 6, 10, 16 and 4 ± 20% gradient Tris/glycine gels (Novex, San Diego, CA, USA). Protein was transferred to PVDF membrane on a Novex electroblot apparatus. For the detection of annexin V, the blots were incubated in 5% BSA in TBST at room temperature for 1 h with constant agitation. Anti-annexin V antibody (A46) was used at 1 : 1000 dilution in TBST with 5% BSA, and the blots were incubated for 1 h. To detect tyrosine-phosphorylated proteins, the blot was incubated in the blocking/incubation buer attached to recombinant anti-phosphotyrosine antibody and following procedure was performed according to the manual's instructions. For the detection of other proteins, the blots were blocked in TBST with 5% nonfat dry milk. Appropriate primary antibodies were used at dierent dilutions in TBST with 5% nonfat dry milk for 1 h. The blots were washed four times with TBST and incubated for 30 min with appropriate horseradish peroxidase-coupled secondary antibodies at a 1 : 1000 or 1 : 2000 dilution in TBST with 5% BSA or 5% nonfat dry milk. Enhanced luminol reagent (NEN Life Science Products, Boston, MA, USA) was used to detect the immunoreactive bands. These bands were quanti®ed by densitometric evaluation (MultiImage TM Light Cabinet and AlphaImager 3.24; Alpha Innotech Corporation, San Leandro, CA, USA).
MAP kinase assay
The eect of TPA on MAPK (ERK1/2) activity was determined by an immune complex kinase assay, using MBP as a substrate. 10 6 cells were plated onto 100 mm culture dish in 10 ml of DMEM with 10% FBS. Cell starvation and treatment with 50 nM TPA for 1 h were performed as above. After washing with ice cold PBS, cells were lysed by adding 500 ml of cold lysis buer A (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 0.5 mM sodium orthovanadate, 0.1% 2-mercaptoethanol, 1% Triton X-100, 50 mM sodium¯uoride, 5 mM sodium pyrophosphate, 10 mM sodium b-glycerophosphate, 0.1 mM phenylmethylsulfonyl uoride, 1 mg/ml each of aprotinin, pepstatin A and leupeptin, 1 mM microcystin, pH 7.4), scraped and sonicated for 5 s on ice. Lysate was clari®ed by centrifuging at 15 800 g for 10 min, normalized for protein content (320 mg each), and subjected to immunoprecipitation with anti-ERK1/2 antibody conjugated agarose suspension (Upstate Biotechnology, Lake Placid, NY, USA). Ten ml of this suspension was aliquoted and washed with lysis buer three times, and ®nal volume was adjusted to 700 ml with lysis buer after adding the cell lysate. After 2 h incubation at 48C, agarose was washed three times with lysis buer and twice with reaction buer (20 mM MOPS, 25 mM b-glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, pH 7.2).
MAP kinase assay was performed at 308C for 20 min in a ®nal volume of 50 ml of reaction buer containing 0.4 mg/ml dephosphorylated MBP, 15 mM magnesium chloride, 100 mM ATP, 4 mM PKC inhibitor peptide, 0.4 mM PKA inhibitor peptide, 4 mM Compound R24571 (Upstate Biotechnology). The reaction was terminated by addition of 50 ml of 26 SDS sample buer. After boiling for 5 min, the products were resolved on 4 ± 20% SDS ± PAGE followed by immunoblotting using anti-phosphorylated MBP antibody at 1 : 100 dilution.
Affinity precipitation of active form Ras (Ras-GTP)
Cells seeded on 100 mm dishes were serum starved and treated with 5 nM TPA for 1 h as described above. After washing with ice cold PBS once, cells were lysed by adding 500 ml of cold lysis buer B (25 mM HEPES, 10 mM magnesium chloride, 150 mM sodium chloride, 1 mM EDTA, 1% Igepal CA630, 1 mM sodium orthovanadate, 0.25% sodium deoxycholate, 10% glycerol, 25 mM sodium¯uoride, 10 mg/ml each of leupeptin and aprotinin, pH 7.4), scraped and sonicated for 5 s on ice. Lysate was clari®ed by centrifugation for 10 min at 15 800 g, normalized for protein content (590 mg in each 0.5 ml), and subjected to anity precipitation of Ras-GTP with 5 ml of agarose suspension conjugated with GST fusion protein corresponding to the human Ras binding domain of Raf-1 (Upstate Biotechnology). After 30 min incubation at 48C, agarose was washed three times with lysis buer B and boiled with 30 ml of 26 SDS sample buer. The product was resolved on 16% SDS ± PAGE followed by immunoblotting using anti-Ras antibody at 1 : 100 dilution.
Immunoprecipitation of Shc associated with Grb2
Cells plated on 100 mm dishes were serum starved and treated with 5 nM TPA for 1 h as described above. After washing with ice cold PBS once, cells were lysed in 1 ml of cold modi®ed RIPA buer (PBS, 1% Igepal CA630, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml phenylmethylsulfonyl¯uoride, 30 ml/ml aprotinin, 1 mM sodium orthovanadate, 1 mg/ml leupeptin, pH 7.5) for 10 min, scraped and sonicated for 10 s twice on ice. Lysate was clari®ed by centrifuging for 10 min at 15 800 g, normalized for protein content (500 mg in each 1 ml), and subjected to immunoprecipitation of Shc associated with Grb2 using 2 mg of polyclonal anti-Shc antibody. After 1 h incubation at 48C, 20 ml of Protein A agarose suspension (Santa Cruz Biotechnology, Inc.) was added followed by 30 min additional incubation at 48C. Agarose was washed three times with modi®ed RIPA buer and boiled with 30 ml of 26 SDS sample buer. The products were resolved on 4 ± 20% SDS ± PAGE followed by immunoblotting using anti-Grb2 antibody at 1 : 100 dilution.
